PCI Biotech Holding ASA (FRA:4QG) Short Percentage of Float

View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of PCI Biotech Holding ASA's Short Percentage of Float

For the Biotechnology subindustry, PCI Biotech Holding ASA's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PCI Biotech Holding ASA's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's Short Percentage of Float falls into.

PCI Biotech Holding ASA (FRA:4QG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (FRA:4QG) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

PCIB:Norway

Address

Ullernchausseen 64, Oslo, NOR, N-0379

Website

https://www.pcibiotech.com

PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.

PCI Biotech Holding ASA (FRA:4QG) Headlines

No Headlines